Vivo Bio Tech share news, announcements and annual reports
NSE: VIVOBIOTBSE: 511509Pharmaceuticals & BiotechnologySmall Cap
Vivo Bio Tech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1994
Last close ₹13.98up ₹0.11 (0.79%)BSE ₹13.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹13.87.
29 Oct: open ₹13.58, high ₹14.09, low ₹13.49
52-week range of BSE trades to 29 Oct 2026
₹12.20Low, 26 Oct 2026₹35.76High, 13 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31 Cr3,302nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.33
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −3.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.60 crore of one-off items, the largest of them in the quarter to Mar 2026.
- −2.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.72
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,84371.4% delivered
Vivo Bio Tech share news and announcements
594 announcements, routine notices left out, newest first. Page 4 of 12.
Jan 2024
4 Jan · Legal
Exchange has sought clarification from Vivo Bio Tech Ltd on January 4, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Dec 2023
Nov 2023
14 Nov · Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Second Quarter And Half Year Ended September 30, 2023
3 Nov · Board meeting
Meeting on 14 Nov 2023: quarterly results
Oct 2023
Sep 2023
18 Sep · Board meeting
Meeting on 21 Sep 2023: preferential issue of shares
Aug 2023
Jul 2023
24 Jul · Board meeting
Meeting on 7 Aug 2023: quarterly results
May 2023
30 May · Related Party Transactions For The Half-Year Ended March 31, 2023
30 May · Audited Standalone And Consolidated Financial Statements For The Fourth Quarter And Year Ended March 31, 2023
18 May · Board meeting
Meeting on 30 May 2023: audited results
Apr 2023
26 Apr · Certificate Under Regulation 40(9) Read With Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023
18 Apr · Compliance Certificate For The Year Ended March 31, 2023
11 Apr · Legal
Exchange has sought clarification from Vivo Bio Tech Ltd on April 10, 2023 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Mar 2023
Feb 2023
Jan 2023
30 Jan · Board meeting
Meeting on 13 Feb 2023: quarterly results
Dec 2022
12 Dec · Board meeting
Meeting on 21 Dec 2022: issue of warrants and preferential issue of shares
Nov 2022
Oct 2022
31 Oct · Board meeting
Meeting on 14 Nov 2022: quarterly results
Sep 2022
29 Sep · Announcement under Regulation 30 (LODR)-Change in Registered Office Address